Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 200

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 200
---
 of ours. As of [●], 2025, we had approximately [●] employees, [●] consultants, and [●] outside directors who were eligible to participate in this Amended and Restated Plan. As stated, the Amended and Restated Plan allows us to grant Awards to consultants, and in certain circumstances, we have granted Awards to individual consultants of the Company performing a critical function. Number of Shares of Common Stock Available Under the Amended and Restated Plan. On [●], 2025, upon recommendation of the Compensation Committee, Aadi’s board of directors approved the addition of an incremental 6,300,000 shares to the Amended and Restated Plan subject to stockholder approval. As of [●], 2025, a total of (i) 2,070,784 shares were authorized for issuance under our 2021 Plan, plus (ii) any shares subject to stock options or similar awards granted under the Aerpio Pharmaceuticals, Inc. 2017 Stock Plan and Incentive Plan or the Aerpio Pharmaceuticals, Inc. 2011 Equity Incentive Plans (the “Prior Plans”) that expire or otherwise terminate without having been exercised in full and shares issued pursuant to awards granted under the Prior Plans that are forfeited to or repurchased by the Company, and (iii) any Shares subject to stock options or similar awards granted under the Aadi Bioscience, Inc. 2014 Equity Incentive Plan that are assumed by the Company pursuant to that certain Merger Agreement entered into between Aadi Bioscience, Inc. and Aerpio Pharmaceuticals, Inc., with the maximum number of shares to be added to the 2021 Plan pursuant to clauses (ii) and (iii) equal to 764,154 shares (the “Rollover Shares”). Upon stockholder approval of the Amended and Restated Plan, the total number of shares authorized for issuance under the Amended and Restated Plan under the preceding clause (i) will be 8,370,784, of which 8,300,284 shares will be available for future awards, plus (x) the remaining Rollover Shares (of which 208,488 remain subject to outstanding awards under the Prior Plans or the Aadi Bioscience, Inc. 2014 Equity Incentive Plan), and (y) any shares added to the Amended and Restated Plan under the “evergreen” provision described below. The shares may be authorized, but unissued or